Willow Review

Is Willow worth it? The short verdict

Willow (startwillow.com) is a straightforward, no-frills telehealth program built around one promise: get a compounded GLP-1 in your hands quickly, evaluated and prescribed by US-licensed doctors, with the medication, the visit, and shipping all rolled into a single monthly price. At $299 a month for compounded semaglutide, it lands above the category median of $170 but well under what brand-name pens cost out of pocket. If you want a clean, mainstream entry point into GLP-1 treatment and you don't need a lot of hand-holding or published fine print, Willow does the core job. If you're the type who wants every program detail spelled out before you sign up, its thin public disclosure may frustrate you.

How Willow's pricing actually works

Willow uses a flat, all-in monthly model rather than charging a separate consult fee on top of the drug. Treatment plans start at $299 per month for compounded semaglutide, and that figure is the real, currently-advertised rate — not a teaser. Compounded tirzepatide sits higher, which is normal across the industry because tirzepatide is the more expensive molecule to source. Willow does not appear to run a discounted first-month promo, so the price you start at is the price you keep. What you get for that monthly charge is bundled:

• Your personalized GLP-1 medication
• Your medical evaluation and a personalized treatment plan
• Unlimited access to your Willow doctor
• Free and discreet shipping

That bundling matters. Some cheaper-looking programs quote a low drug price and then add visit fees, dose-escalation surcharges, or shipping. Willow's number is meant to be the number, which makes it easy to compare against the median and against the over-a-thousand-dollars-a-month list price of brand pens without insurance.

The medications — and the format choice that sets it apart

Here's where Willow genuinely differentiates itself. Most compounding telehealth shops offer injections only. Willow offers three options: compounded semaglutide injection, compounded semaglutide sublingual tablets, and compounded tirzepatide injection. The sublingual tablet is the standout — it's aimed squarely at people who are needle-averse and have been putting off GLP-1 treatment for that reason. If the only thing keeping you from starting is the syringe, Willow is one of the few mainstream options that gives you a real alternative.

Be clear-eyed about what 'compounded' means, though. These are not the FDA-approved brand products (Wegovy, Ozempic, Zepbound, Mounjaro); they're compounded versions of semaglutide and tirzepatide made by compounding pharmacies. They can be a legitimate, lower-cost route, but they don't carry the same regulatory review as a branded pen, and Willow does not list a brand-name option.

Who should choose Willow — and who should skip it

Choose Willow if you want a simple, single-price program, if you specifically want a sublingual (no-needle) semaglutide option, or if you want both semaglutide and tirzepatide available from the same provider so you can switch molecules without changing services.

Skip Willow, or at least ask questions first, if you need brand-name medication, if you rely on insurance billing (this is a cash-pay compounded model), or if you live somewhere Willow may not serve — the company does not publicly publish its state availability list, so you'll want to confirm your state is covered before you pay.

Trust, safety, and what we couldn't verify

On the reassuring side, Willow prescribes through US-licensed doctors and gives you unlimited access to that doctor as part of the plan, which is the kind of ongoing oversight you want on a GLP-1. There are no FDA warning letters on file against Willow in our records, and nothing in the data suggests a safety problem.

The honest caveat is transparency. Willow discloses less publicly than the strongest providers do: it does not name its compounding pharmacy or share that pharmacy's accreditation, and it does not publish its list of available states. Those gaps don't make Willow unsafe, but they do lower how much we can independently confirm, and they're the main reason a cautious shopper should treat the $299 headline as a starting point and verify the program specifics directly before committing. You can see how we weigh disclosure and oversight in our scoring methodology.

Bottom line

Willow is a solid mainstream choice for compounded GLP-1 access at $299 a month, and its sublingual tablet plus dual semaglutide/tirzepatide lineup give it a real reason to exist beyond price. The trade-off is thin public information — undisclosed pharmacy and undisclosed states — so confirm the details that matter to you before you buy. For needle-averse patients especially, it's worth a look.

Shopping around? Direct Meds ($249/month) and Embody ($299/month) are the nearest alternatives to Willow in our rankings.